diagnostic performance of f-18 fdg pet/ct in patients with cancer of unknown primary: additional benefit over ct-based conventional work up
Authors
abstract
background: in the era of well-developed site-specific treatment strategies in cancer, identification of occult primary is of paramount importance in cup patients. furthermore, exact determination of the extent of the disease may help in optimizing treatment planning. the aim of the present study was to investigate additional value of f-18 fdg pet/ct in patients with cancer of unknown primary (cup) as an appropriate imaging tool in early phase of initial standard work up. m aterials and methods: sixty-two newly diagnosed cup patients with inconclusive diagnostic ct scan of chest, abdomen and pelvis referring for f-18 fdg pet/ct were enrolled in this study. standard of reference was defined as histopathology, other diagnostic procedures and a 3-month formal clinical follow up. the results of pet/ct were categorized as suggestion for primary site and additional metastasis and classified as true positive, false positive, false negative and true negative. the impact of additional metastasis revealed by f-18 fdg pet/ct on treatment planning and the time contribution of f-18 fdg pet/ct in diagnostic pathway was investigated. r es ults: sixty-two patients with mean age of 62 (30 men, 32 women), pet/ct correctly identified primary origin in 32% with false positive rate of 14.8%. no primary lesion was detected after negative pet/ct according to standard of reference. sensitivity, specificity and accuracy were 100%, 78% and 85%, respectively. additional metastatic site was found in 56% with 22% impact on treatment planning. time contribution for pet/ct was 10% of total diagnostic pathway. conclusion: providing higher detection rate of primary origin with excellent diagnostic performance, shortening the diagnostic pathway and improving treatment planning, f-18 fdg pet/ct may play a major role in diagnostic work up of cup patients and may be recommended as an alternative imaging tool in early phase of investigation.
similar resources
Diagnostic performance of 18F-FDG PET-CT in patients presenting with secondary neck nodes from an unknown primary
Introduction: Clinical examination and even anatomical imaging may fail to identify primary site of malignancy in patients presenting with cervical nodal metastasis. 18F-Fluorodeoxyglucose Positron Emission Computed Tomography (18F-FDG PET-CT) is known to overcome the limitations of anatomic imaging. Methods: Sixty-three (63) patient...
full textF-FDG PET/CT in Patients with Cancer of Unknown Primary Site
Received 10/6/2008; revised 11/24/2008; accepted 1/5/2009. For correspondence and reprints contact: Yu-Wen Chen, M.D., Department of Nuclear Medicine, Chung-Ho Memorial Hospital, Kaohsiung Medical University. 100 Tz You 1st Road, San-Ming District, Kaohsiung 807, Taiwan. Tel: (886)73121101 ext. 7152, E-mail: [email protected] Objective: This retrospective study was undertaken to address the...
full textF-18 FDG PET/CT imaging of primary hepatic neuroendocrine tumor
Primary hepatic neuroendocrine tumors (PHNETs) are extremely rare neoplasms. Herein, we report a case of a 70-year-old man with a hepatic mass. The non-contrast computed tomography (CT) image showed a low-density mass, and dynamic CT images indicated the enhancement of the mass in the arterial phase and early washout in the late phase. F18- fluorodeoxyglucose (18F-FDG) positron emission tomogra...
full textDetection of chordoma recurrence by F-18 FDG-PET/CT
Background: Despite the relative success of surgical resection followed by proton, proton/photon, or conventional radiotherapy in terms of recurrence-free survival, chordomas are still associated with a high rate of recurrence. To our knowledge there are only very few reported cases of this rare tumor detected by F-18 FDG-PET. Materials and Methods: In this case we show the significanc...
full textMy Resources
Save resource for easier access later
Journal title:
novelty in biomedicineجلد ۴، شماره ۱، صفحات ۵-۱۲
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023